For example, in non-small cell lung cancer tissues, GPSM2 was found to be downregulated, and the silencing of GPSM2 enhances the metastatic potential of cancer cells in both in vitro and in vivo environments. Here, GPSM2 is linked to non-small cell lung carcinoma.